Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000950170-25-045642
Filing Date
2025-03-26
Accepted
2025-03-26 21:30:04
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 17933
  Complete submission text file 0000950170-25-045642.txt   19840
Mailing Address 4330 LA JOLLA VILLAGE DRIVE SUITE 200 SAN DIEGO CA 92122
Business Address 4330 LA JOLLA VILLAGE DRIVE SUITE 200 SAN DIEGO CA 92122 855-293-2639
BIORA THERAPEUTICS, INC. (Subject) CIK: 0001580063 (see all company filings)

EIN.: 273950390 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-91551 | Film No.: 25774926
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 505 FIFTH AVENUE, FLOOR 18 NEW YORK NY 10017
Business Address 505 FIFTH AVENUE, FLOOR 18 NEW YORK NY 10017 646-434-1636
Athyrium Opportunities III Co-Invest 1 LP (Filed by) CIK: 0001815260 (see all company filings)

EIN.: 821097086 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A